CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma

N/ANot Yet RecruitingNCT07823959

Assiut University60 enrolled

Overview

Multiple myeloma is a type of blood cancer characterized by the abnormal growth of plasma cells in the bone marrow. Increasing evidence indicates that interactions between myeloma cells and the host immune-inflammatory response influence disease behavior and patient outcomes. Inflammatory markers calculated from routine complete blood count (CBC) tests, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), offer simple, inexpensive ways to assess systemic inflammation. However, how these markers correlate with baseline clinical presentation, laboratory disease burden, and tumor cell immunophenotypes remains insufficiently explored. The primary purpose of this cross-sectional study is to evaluate the association between CBC-based inflammatory indices and clinical and laboratory measures of disease severity in patients with newly diagnosed multiple myeloma prior to the start of anti-myeloma therapy. The study will also examine the relationship between these inflammatory indices and the specific immunophenotypic characteristics of neoplastic plasma cells identified via bone marrow flow cytometry. A total of 60 patients with newly diagnosed multiple myeloma presenting to Assiut University Hospital and the South Egypt Cancer Institute will be enrolled. Baseline demographic and clinical data (including CRAB manifestations and ISS/R-ISS staging), routine blood laboratory results (including albumin, beta-2 microglobulin, and LDH), bone marrow plasma cell percentages, and flow cytometric findings will be collected and analyzed.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Multiple Myeloma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Newly diagnosed Multiple Myeloma patients, evaluated prior to the initiation of anti-myeloma therapy * Both sexes, with no age restriction Exclusion Criteria: * Prior receipt of anti-myeloma treatment * Concurrent active malignancies or other hematological disorders * Presence of acute or chronic inflammatory or infectious conditions that may influence systemic inflammatory indices * Concomitant use of medications that significantly alter inflammatory or hematological parameters

Outcomes

Primary Outcomes

Bone Marrow Plasma Cell Percentage

The percentage of clonal plasma cells quantified on bone marrow aspirate/biopsy smears at diagnosis. This parameter serves as the primary objective measure of tumor burden and disease severity to evaluate its relationship with baseline complete blood count (CBC)-derived inflammatory indices (specifically the neutrophil-to-lymphocyte ratio \[NLR\]).

Time frame: Baseline